application:It is use for imatinib Mesylate intermediates.
description:Imatinib (INN), marketed by Novartis as Gleevec (U.S.) or Glivec (Europe/Australia/Latin America), is a competitive tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).Like all tyrosine-kinase inhibitors, imatinib works by preventing a central tyrosine kinase enzyme, in this case BCR-Abl, from phosphorylating subsequent proteins and initiating the signaling cascade necessary for cancer development, thus preventing the growth of cancer cells and leading to their death by apoptosis.Because the BCR-Abl tyrosine kinase enzyme exists only in cancer cells and not in healthy cells, imatinib works as a form of targeted therapy—only cancer cells are killed through the drug's action.In this regard, imatinib was one of the first cancer therapies to show the potential for such targeted action, and is often cited as a paradigm for research in cancer therapeutics.
Please at any time if you are interested in Imatinib.
If you want to know about Imatinib price , please call our Customer Services Hotline +86 592 5365887 or send the email to firstname.lastname@example.org.
Tel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Leave a Message
We will contact you within 24 hours.